Europe Dermal Fillers Market Size, Share & COVID-19 Impact Analysis, By Material (Hyaluronic Acid, Calcium Hydroxylapatite, Poly-L-lactic Acid, PMMA (Poly (Methyl Methacrylate)), Fat Fillers, and Others), By Product (Biodegradable and Non-biodegradable), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration of Volume/Fullness, and Others), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2022-2029

The Europe dermal fillers market size was valued at USD 1.41 billion in 2021 and is projected to grow from USD 1.46 billion in 2022 to USD 2.25 billion by 2029, exhibiting a CAGR of 6.3% during the forecast period. Based on our analysis, the market exhibited a decline of -23.3% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with dermal fillers experiencing lower-than-anticipated demand across Europe compared to pre-pandemic levels.

Dermal filler injections are a type of nonsurgical cosmetic procedure carried out to correct wrinkles, smoothen lines, and restore facial volumes. These products enhance facial features, giving individuals a more youthful appearance. Their adoption has risen due to the increase in disposable incomes and changes in attitude of European consumers toward non-surgical procedures for improving their aesthetic appearance. High degree of safety and satisfactory patient outcomes make these procedures highly demandable among consumers in the Europe region. Therefore, due to these factors, the Europe market is expected to reach a substantial market size in 2029.

Growing adoption of dermal fillers has led key market players in the region to increase their R&D investments for introducing new products. Citing an instance, in April 2021, Merz Pharma UK Ltd announced the launch of BELOTERO BALANCE (+), a lidocaine formulation of BELOTERO BALANCE in the U.K. and Ireland. Similar efforts from leading players will accelerate the Europe dermal fillers market growth during the forecast duration.

COVID-19 IMPACT

Decline in Non-Elective Procedures amid Pandemic Impacted the Market Growth Negatively

COVID-19 had a negative impact on the market growth during FY 2020 due to a drop in non-COVID-related healthcare services and procedures in light of the restrictions imposed by the respective governments. The pandemic disrupted the European cosmetics products market owing to a substantial reduction in procedural volumes as the outbreak resulted in disruptions in supply chains of several companies. Also, due to limitations on import and export, various cosmetic procedure appointments were delayed. Hence, the sector witnessed disruptions in supply chains in FY 2020. Key market players including Allergan Aesthetics (AbbVie Inc.) reported a decline in their revenues for FY 2020 compared to FY 2019.

• As per a 2021 article published by Pharmaceutical Technology, over 81% of U.K.-based aesthetic businesses were forced to close their clinics during COVID-19 to minimize health risk and burden on healthcare systems. In addition, the revenues of 67% of companies declined.

However, in 2021, the restrictions were eased, and many pent-up and postponed procedures across cosmetics centers and specialty clinics resumed. Clinics and dermatology centers saw a 70% increase in virtual consultation requests during the lockdown, which contributed to the market growth.

• In FY 2021, the international geographical segment of Allergan Aesthetics (AbbVie, Inc.), which includes the Europe region, generated a revenue of USD 877.0 million for their Juvederm Collection, with an increase of 119.3%, compared to 2020.

From 2022 onwards, the market is estimated to witness a steady growth over 2022-2029 as the number of minimal invasive procedures involving soft tissue fillers are anticipated to increase, leading to a surge in the demand for fillers and other cosmetic surgeries.

LATEST TRENDS

Wider Adoption Among the Male Population Offers New Growth Opportunities

The recent industry trends show an emerging interest in minimally-invasive cosmetic procedures across nearly all demographic groups. The male demographic population, in particular, has developed greater interest in skin-enhancing procedures to up their appearances. A wider percentage of men are aware of the negative impacts of aging on the skin and the appearance of their facial features. With unprecedented access to social media and other sources, a lot more men in the Europe region are seeking new ways to reverse the effect of early gravitational aging, which primarily affects the skin on the face. The benefits of dermal injectables such as minimal risk and low downtime make them highly popular among men, which will create new opportunities for market players in the coming years.

DRIVING FACTORS

Increasing Demand for Minimal-Invasive Cosmetic Procedure will Drive the Market Growth

One of the major driving factors of the market is the rising demand for non-surgical procedures across European countries. People are seeking easier and comparatively pain-free methods for appearing youthful and healthy without the problems or hassles of invasive cosmetic surgery. Also, these invasive cosmetic procedures often have several repercussions, which require the patients to take additional days to recover. These factors have also paved the way for significant mergers, research collaborations, and partnerships, leveraging the synergistic benefits of R&D.

• According to 2020 data from the International Society of Aesthetic Plastic Surgery (ISAPS), Germany had 731,883 non-surgical procedures, while Italy had 585,468, Spain 231,606, and Greece 318,903.  

The surge in demand for these types of cosmetic procedures has also led to a rise in the demand for several dermatological and non-invasive cosmetic solutions. Various companies involved in this field are increasingly introducing new products to meet the evolving demand for medical aesthetics.

• In February 2021, Hy-Silk, a new dermal filler product of Contipro a.s., is made from silk fibroin lixivium and received the CE approval ahead of its U.K. launch.

Greater Focus over R&D by Key Players to Accelerate Market Growth

Another critical factor driving the market growth is the increased emphasis by key players over R&D to support and accelerate the development of new products. As the awareness regarding non-invasive procedures increases, the adoption of these products in various application areas also rises, which further contributes to market expansion.

• For instance, in June 2020, BioScience GmbH, a Germany-based company received an extension in their CE mark by the European Commission for its hyaluronic acid dermal fillers line which includes HYAcorp, Genefill, and Hyaprof.

RESTRAINING FACTORS

High Treatment Cost and Relative Side Effects to Limit the Market Growth 

Despite growing popularity and adoption, the high cost of dermal filling hampers its demand to some extent. This cost varies based on the expertise and qualification of the healthcare professional. In addition, the time and efforts needed to perform these aesthetic procedures varies patient to patient. As cosmetic solutions only offer a temporary effect, over a period of time there may be a need for repetition, which translates into significant spending.

• As a number of fillers are biodegradable, the patient is expected to have repeated and consistent treatments in order to maintain their appearance. Moreover, not all insurance companies extend insurance coverage for these cosmetic procedures. These factors may lead patients to not opt for re-procedures.

The administration of skin injectables such as fillers may cause certain harmful side effects, which may lead to swelling, infections at the injection site, development of lumps and bumps, redness, and bruising, among other complications. The aforementioned factors could hamper the market growth in the forthcoming years.

SEGMENTATION

By Material Analysis

Wider Awareness of Benefits of Hyaluronic Acid will Drive Market Growth over 2022-2029

Based on material, the market is classified into hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, fat fillers, PMMA (poly (methyl methacrylate)), and others.

The hyaluronic acid segment dominated the Europe dermal fillers market share in 2021. It is anticipated to rise at the highest CAGR during 2022-2029. The growth is primarily driven by the safety and comparative longevity it offers coupled with the presence of key companies offering these products for various applications. For instance, in March 2021, Joonghun Pharmaceuticals launched a premium cross-linked hyaluronic acid dermal filler, Artgaon, which received the CE mark to target the Europe market.

Calcium hydroxylapatite and poly l lactic acid held significant shares in 2021 due to successful and improved outcomes of these products in various aesthetic indications. For instance, injectable microspheres of calcium hydroxylapatite have been successfully used for the correction of lipoatrophy of HIV patients receiving antiprotease treatment and also to smoothen moderate wrinkles.

The PMMA segment is slated to record the second-highest CAGR due to the increase in permanent correction procedures such as nasolabial folds and deep glabellar lines.

By Product Analysis

Biodegradable Segment to Dominate Market Owing to Better Safety

By product, the market is segmented into biodegradable and non-biodegradable. The biodegradable segment has driven the market in 2021, owing to the rising preference of consumers for biodegradable dermal fillers. This gradual shift is attributed to the greater degree of safety features it offers along with minimal adverse side effects, leading to the segment’s growth during the forecast period.

The non-biodegradable segment is likely to lose market share over the forecast period due to its several disadvantages, including more severe side-effects compared to biodegradable fillers. In case of treatment with non-biodegradable products, there is no ‘wearing off’ or ‘reversing of the fillers. Also, if the injector makes a mistake or if there is any miscommunication between the healthcare professional and the patient’s needs, there is a limited scope of reversal with these products.

By Application Analysis

Wrinkle Correction Treatment to See Robust Demand Owing to Increasing Awareness

Based on application, the market is segmented into restoration of volume/fullness, wrinkle correction treatment, scar treatment, lip enhancement, and others.

The wrinkle correction treatment segment held the maximum market share in 2021 and is estimated to witness the fastest CAGR during the forecast period. The growth is attributed to the rising awareness regarding effectiveness of these products in facial line correction treatment amongst people with aging related concerns. For instance, Allergan Aesthetics’ JUVÉDERM VOLLURE XC has been approved for use in Europe since 2013 for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. The availability of established products leads to increased procedural volumes for this indication, leading to the segment’s growth.

The lip enhancement segment is anticipated to rise at the second-highest CAGR during 2022-2029. The rising awareness amongst the women toward lip aesthetics and the growing spending capacity of the population are some of the reasons attracting key players to invest in the development and introduction of innovative lip enhancement products in the market.  

Restoration of volume/fullness accounted for the third largest market share and is projected to record a substantial CAGR over 2022-2029. Rising adoption of these products amongst the female population for volumetric rejuvenation of facial volume, which gets lost with age, is anticipated to fuel the segment’s growth.

Scar treatment and others segments are anticipated to grow at a comparatively lower CAGR during the forecast period. However, these products offer collagen boosting properties that accelerate the natural healing process in the respective area. Such benefits will offer a lucrative growth opportunity, enhancing the adoption rate of skin injectables for scar treatment.

By End-user Analysis

Rising Preference of Procedures in Specialty & Dermatology Clinics is Likely to Propel the Segment’s Dominance 

By end-user, the market is classified into hospitals & clinics, specialty & dermatology clinics, and others.

Specialty & dermatology clinics segment dominated with maximum market share in 2021 and is anticipated to record the highest CAGR over the projected timeframe. The growing patient preference toward specialty & dermatology clinics coupled with strong procedural volumes of these products in these settings for several aesthetic indications is favoring the expansion of the segment.

The hospitals & clinics segment held the second largest market share in 2021, owing to the rising number of cosmetic procedures performed in hospitals & clinics settings. For instance, various hospitals and clinics in the U.K. offer dermal fillers injections for several skin problems, which include some of the most common aging signs around the eyes and forehead, including ‘laughter lines’, ‘frown lines’, and ‘crow’s feet’. The others segment is slated to record a lower CAGR during 2022-2029.

REGIONAL INSIGHTS

On the basis of country/sub-region, the Europe dermal fillers market is segmented into Germany, the U.K., France, Italy, Spain, Scandinavia, and the Rest of Europe.

The Germany market size was valued at USD 0.35 billion in 2021 and will dominate the global market throughout the forecast period. The dominance of this country is attributed to the presence of advanced healthcare infrastructure and high awareness amongst the populace about cosmetic procedures leading to a strong increase in the procedural volume. The 2020 data from ISAPS shows that Germany had over 1,157,738 procedures, out of which injectables-based non-surgical procedures constituted 695,315.

In terms of revenue, France holds the second-largest market share, owing to strategic initiatives taken by market players to increase their market presence coupled with the consistent increase in non-surgical procedures. For instance, in January 2020, Merz Pharma presented data of its aesthetics product portfolio at the International Master Course on Aging Science (IMCAS) World Congress, which was held from 30 January to 1 February 2020 in Paris, France.

The U.K. market is expected to reach at the highest CAGR during 2022-2029 due to the increasing consciousness about physical appearance amongst the population. These factors are encouraging the adoption of correction procedures, which is attracting the industry players to engage in investment initiatives and introduce new products to support the market growth in the country. For instance, according to the Review of the Regulation of Cosmetic Interventions of the U.K., amongst the cosmetic procedures conducted in the U.K., non-surgical treatments such as Botox and dermal fillers accounted for nine out of ten procedures. Italy and Spain held significant market shares in 2021 and will exhibit robust growth rates in future,

Scandinavia and the rest of Europe relatively held smaller market shares in 2021 and are likely to witness lower CAGRs during 2022-2029. Limited number of these cosmetic procedures in these countries and a lower presence of related healthcare professionals including cosmetic surgeons are some of the factors responsible for the slower growth in these countries.

KEY INDUSTRY PLAYERS

Allergan Aesthetics (AbbVie Inc.) Occupied Peak Market Position Owing to Robust Product Portfolio in 2021

In terms of competitive landscape, Allergan Aesthetics (AbbVie), Galderma and Merz Pharma are the key players of the Europe market due to strong product offerings, active involvement in R&D investments for the acceleration of product launches and approvals in the forecast period. Allergan Aesthetics (AbbVie Inc.) is leading in terms of market presence owing to its established product portfolio of the Juvederm Collection as well as launching new products such as HArmonyCa. The product offers dual effects with the presence of two materials such as hyaluronic acid and calcium hydroxyapatite. The product has recently been launched in Europe.

Other prominent players, such as Galderma and Merz Pharma, are also leading the market due to their strong distribution network coupled with diverse aesthetic indications for their product portfolio, which includes HA fillers. Galderma is maintaining its market position by strategic executions such as the re-launch of its product Sculptra in Europe. Merz Pharma occupies a substantial share due to its extensive portfolio, which includes Radiesse and BELOTERO. Merz is also focusing on expanding its market presence by launching products such as BELOTERO BALANCE in key countries of Europe. Some of the other major players are Sinclair Pharma, Revance Therapeutics, Inc., and others. These companies are focused on strengthening their product portfolio and distribution networks through strategic collaboration and partnerships to increase their market share in the Europe market.

LIST OF KEY COMPANIES PROFILED:

• Allergan Aesthetics (AbbVie Inc.) (U.S.)


• Merz Pharma (Germany)


• Galderma (Switzerland)


• Revance Therapeutics, Inc. (U.S.)


• Sinclair Pharma (U.K.)


• BIOPLUS CO., LTD. (South Korea)


• Bioxis pharmaceuticals (France)


• Teoxane (Switzerland)


• DR. Korman (Israel)


• Zimmer Aesthetics (Germany)

KEY INDUSTRY DEVELOPMENTS:

• March 2022: Allergan Aesthetics rolled out the HArmonyCa with lidocaine in Europe. The product is a dual effect hybrid filler with calcium hydroxyapatite and hyaluronic acid as its active ingredients.


• March 2022: Hallura Ltd. announced that their next-generation BiOLinkMatrix Hyaluronic Acid (HA) dermal fillers reported successful topline results in a multi-site European clinical trial for three indications: lips, nasolabial folds correction, and cheeks enhancement.


• September 2021: Galderma and Sofregen partnered to develop the next-gen of bio-stimulator fillers using silk-based technology.


• August 2021: Prollenium Medical Technologies launched its new dermal filler brand Revanesse in the U.K.


• March 2021: Galderma re-launched of Sculptra, an injectable poly-L-lactic Acid, in the European region with an updated administration protocol.

REPORT COVERAGE

The research report provides qualitative and quantitative insights on the market and a detailed analysis of the Europe market size & growth rate for all possible segments in the market. Along with the Europe market forecast, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights presented in the report are an overview of the number of procedures, an overview of price analysis of types of products, an overview of the regulatory scenario by key countries, pipeline analysis, new product launches, key industry developments (mergers, acquisitions & partnerships), and the impact of COVID-19 on the market.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2018-2029
Base Year	2021
Forecast Period	2022-2029
Historical Period	2018-2020
Unit	Value (USD billion)
Segmentation	By Material, Product, Application, End-user, and Country/Sub-Region
By Material	Hyaluronic Acid Calcium Hydroxylapatite Poly-L-lactic Acid PMMA (Poly (Methyl Methacrylate)) Fat Fillers Others
By Product	Biodegradable Non-biodegradable
By Application	Scar Treatment Wrinkle Correction Treatment Lip Enhancement Restoration of Volume/Fullness Others
By End-user	Specialty & Dermatology Clinics Hospitals & Clinics Others
By Country/Sub-Region	Germany (By Material) U.K. (By Material) France (By Material) Italy (By Material) Spain (By Material) Scandinavia (By Material) Rest of Europe (By Material)